

| | |
|---|-----------------|
| Total number of patients (n) | 1438 |
| Age (years \pm SD) | 54.9 \pm 14.9 |
| Females, n (%) | 849 (59 %) |
| Diagnosis, n (%) | |
| Rheumatoid arthritis | 500 (34.8 %) |
| Psoriatic arthritis | 378 (26.3 %) |
| Ankylosing spondylitis | 309 (21.5 %) |
| Unspecified polyarthritis | 77 (5.4 %) |
| Not registered | 48 (3.3 %) |
| Reactive arthritis | 37 (2.6 %) |
| Systemic lupus erythematosus | 19 (1.3 %) |
| Juvenile idiopathic arthritis | 13 (0.9%) |
| Giant cell arteritis | 10 (0.7%) |
| Other disorders/diagnosis | 47 (3.3 %) |
| Targeted DMARDS, n (%) | |
| TNF inhibitors | 1225 (85.2 %) |
| <i>Infliximab</i> | 436 (30.3 %) |
| <i>Etanercept</i> | 343 (23.9 %) |
| <i>Adalimumab</i> | 309 (21.5 %) |
| <i>Golimumab</i> | 137 (9.5 %) |
| <i>Certolizumab</i> | 3 (0.2%) |
| Tocilizumab | 82 (5.7 %) |
| Secukinumab | 51 (3.5 %) |
| Rituximab | 26 (1.8 %) |
| Belimumab | 17 (1.2 %) |
| Tofacitinib | 10 (0.7 %) |
| Abatacept | 9 (0.6 %) |
| Ustekinumab | 8 (0.6 %) |
| Anakinra | 5 (0.4%) |
| Apremilast | 2 (0.1 %) |
| <i>Table S2</i> | |
| <i>Baseline demographics of 1438 rheumatic patients in ICEBIO in respect to disease and treatment</i> | |